5,138 Shares in Novo Nordisk A/S (NVO) Acquired by BTC Capital Management Inc.
BTC Capital Management Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, Holdings Channel reports. The institutional investor acquired 5,138 shares of the company’s stock, valued at approximately $221,000.
Other institutional investors also recently bought and sold shares of the company. Huntington National Bank increased its position in Novo Nordisk A/S by 119.5% in the first quarter. Huntington National Bank now owns 18,103 shares of the company’s stock valued at $620,000 after buying an additional 9,857 shares during the period. Ledyard National Bank increased its position in Novo Nordisk A/S by 225.5% in the first quarter. Ledyard National Bank now owns 145,322 shares of the company’s stock valued at $4,982,000 after buying an additional 100,670 shares during the period. Alta Capital Management LLC increased its position in Novo Nordisk A/S by 11.1% in the first quarter. Alta Capital Management LLC now owns 922,362 shares of the company’s stock valued at $31,618,000 after buying an additional 92,509 shares during the period. Reliance Trust Co. of Delaware increased its position in Novo Nordisk A/S by 42.3% in the first quarter. Reliance Trust Co. of Delaware now owns 22,977 shares of the company’s stock valued at $788,000 after buying an additional 6,829 shares during the period. Finally, Howland Capital Management LLC bought a new position in Novo Nordisk A/S during the first quarter valued at about $266,000. Hedge funds and other institutional investors own 6.40% of the company’s stock.
Novo Nordisk A/S (NYSE NVO) opened at 45.81 on Friday. Novo Nordisk A/S has a one year low of $30.89 and a one year high of $47.98. The firm has a market cap of $113.68 billion, a P/E ratio of 18.74 and a beta of 0.63. The company has a 50-day moving average of $42.76 and a 200 day moving average of $38.81.
The firm also recently announced an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be paid a dividend of $0.336 per share. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend is Friday, August 18th. This represents a yield of 1.07%. Novo Nordisk A/S’s payout ratio is presently 36.00%.
Several equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Wednesday, June 21st. Finally, TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $53.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.